Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Structural maintenance of chromosomes protein 2 (SMC2) is a central component of the condensin complex, which is required for transforming interphase chromatin into mitotic chromosomes and proper chromosome segregation during cell division[1][2][6]. SMC2 forms a heterodimer with SMC4, providing the ATPase activity that powers condensin-mediated supercoiling and compaction of DNA. It is essential for cell proliferation and is implicated in carcinogenesis, as its overexpression promotes tumor cell growth while its inhibition results in mitotic defects and apoptotic cell death[1][6]. Mutations or deletions in the SMC2 gene are associated with developmental syndromes such as Cornelia de Lange syndrome[1][2]. SMC2 is being explored as a potential therapeutic target in oncology due to its critical role in cancer cell proliferation[6].
Knockdown or inhibition of SMC2 leads to mitotic catastrophe and cell death in cancer cells[6]. Potential induction of apoptosis through disruption of chromosome condensation and division.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Structural maintenance of chromosomes protein 2 (SMC2).